Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 18/20 | 0.58 |
| ▸ | MMP13 | P45452 | 12/20 | 0.47 |
| ▸ | MMP9 | P14780 | 10/20 | 0.47 |
| ▸ | ADAM17 | P78536 | 6/20 | 0.47 |
| ▸ | MMP3 | P08254 | 7/20 | 0.46 |
| ▸ | MMP2 | P08253 | 5/20 | 0.46 |
| ▸ | PDE4A | P27815 | 3/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | MMP14 | P50281 | 1/20 | 0.44 |
| ▸ | MMP16 | P51512 | 1/20 | 0.44 |
| ▸ | MMP7 | P09237 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6823262 | 0.83 | MMP1 (0.59) | MMP1MMP13MMP9ADAM17MMP3 | |
| SCHEMBL7309090 | 0.76 | MMP1 (0.80) | MMP1MMP13MMP9ADAM17MMP3 | |
| SCHEMBL7301387 | 0.75 | MMP1 (0.79) | MMP1MMP13MMP9ADAM17MMP3 | |
| SCHEMBL7303077 | 0.74 | MMP1 (0.72) | MMP1MMP13MMP9ADAM17MMP3 | |
| SCHEMBL7307897 | 0.73 | MMP1 (1.00) | MMP1MMP13MMP9MMP3MMP2 | |
| SCHEMBL7299253 | 0.73 | MMP1 (0.76) | MMP1MMP13MMP9ADAM17MMP3 | |
| SCHEMBL7308211 | 0.73 | MMP1 (0.76) | MMP1MMP13MMP9ADAM17MMP3 | |
| SCHEMBL7301736 | 0.72 | MMP1 (0.70) | MMP1MMP13MMP9ADAM17MMP3 | |
| SCHEMBL7299271 | 0.72 | MMP1 (0.66) | MMP1MMP13MMP9ADAM17MMP3 | |
| SCHEMBL7307783 | 0.70 | MMP1 (0.66) | MMP1MMP13MMP9ADAM17MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6057369-A | USE IN THE TREATMENT OF DISEASE STATES ASSOCIATED WITH PROTEINS THAT MEDIATE CELLULAR ACTIVITY WHICH ARE CAPABLE OF BEING MODULATED BY INHIBITING A MATRIX METALLOPROTEINASE (MMP), TUMOR NECROSIS FACTOR (TNF) OR CYCLIC AMP | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 2000-05-02 | — | — | US | claimed |
| EP-0871439-A4 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE POULENC RORER PHARMA (US) | 1999-07-21 | — | — | EP | claimed |
| EP-0871439-A1 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1998-10-21 | — | — | EP | claimed |
| WO-1997024117-A1 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-10 | — | — | WO | claimed |
| EP-0871439-B1 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | AVENTIS PHARMA INC (US) | 2004-03-31 | — | — | EP | disclosed |
| US-6057369-A | USE IN THE TREATMENT OF DISEASE STATES ASSOCIATED WITH PROTEINS THAT MEDIATE CELLULAR ACTIVITY WHICH ARE CAPABLE OF BEING MODULATED BY INHIBITING A MATRIX METALLOPROTEINASE (MMP), TUMOR NECROSIS FACTOR (TNF) OR CYCLIC AMP | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 2000-05-02 | — | — | US | disclosed |
| EP-0871439-A4 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE POULENC RORER PHARMA (US) | 1999-07-21 | — | — | EP | disclosed |
| EP-0871439-A1 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1998-10-21 | — | — | EP | disclosed |
| WO-1997024117-A1 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-10 | — | — | WO | disclosed |